Quality of Life for Children With Functional Abdominal Pain: A Comparison Study of Patients' and Parents' Perceptions

The main objective of this study was to preliminary explore the effects of DARWeb on different outcomes. A Quasi-experimental, one-group, pretest–posttest design was used. Parents and children were asked to complete questionnaires and questions (separately) about quality of life, abdominal pain severity, and satisfaction. Semi-structured interviews with families were also performed. This study focuses on 17 families. Results showed that parent’s ratings of children’s abdominal pain severity were significantly lower after finishing the intervention and at the 3-month follow-up, and quality of life scores had increased significantly after 3 months. From children’s ratings, mean abdominal pain severity scores were significantly lower after the intervention compared to the preintervention assessment. Both parents and children were quite satisfied with the intervention. In qualitative interviews, families suggested that DARWeb helped them to give less importance to pain and to learn coping strategies. In conclusion, this study showed the potential usefulness of DARWeb for children with functional abdominal pain and for their parents.

Download Full-text

Nausea exacerbates symptom burden, quality of life, and functioning in adolescents with functional abdominal pain disorders

Neurogastroenterology & Motility ◽

10.1111/nmo.13595 ◽

2019 ◽

pp. e13595 ◽

Cited By ~ 3

Author(s):

Katja Kovacic ◽

Prasanna K. Kapavarapu ◽

Manu R. Sood ◽

B U. K. Li ◽

Melodee Nugent ◽

...

Keyword(s):

Quality Of Life ◽

Abdominal Pain ◽

Symptom Burden ◽

Functional Abdominal Pain

Download Full-text

Quality of life among parents seeking treatment for their child’s functional abdominal pain

Quality of Life Research ◽

10.1007/s11136-018-1916-2 ◽

2018 ◽

Vol 27 (10) ◽

pp. 2557-2570 ◽

Cited By ~ 5

Author(s):

Claudia Calvano ◽

Petra Warschburger

Keyword(s):

Quality Of Life ◽

Abdominal Pain ◽

Functional Abdominal Pain

Download Full-text

Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review

Therapeutic Advances in Gastroenterology ◽

10.1177/1756284821993586 ◽

2021 ◽

Vol 14 ◽

pp. 175628482199358

Author(s):

Nikita Hanning ◽

Adam L. Edwinson ◽

Hannah Ceuleers ◽

Stephanie A. Peters ◽

Joris G. De Man ◽

...

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Irritable Bowel Syndrome ◽

Abdominal Pain ◽

Barrier Function ◽

Significant Proportion ◽

Healthy Controls ◽

Barrier Dysfunction ◽

Irritable Bowel

Background and Aim: Irritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life. Methods: A comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both in vivo and in vitro studies were considered. Results: We identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17–50%), IBS-D (37–62%) and IBS-C (4–25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies). Conclusions: Barrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.

Download Full-text

Addison’s Disease Presenting with Abdominal Pain

Acute Medicine Journal ◽

10.52964/amja.0141 ◽

2006 ◽

Vol 5 (3) ◽

pp. 102-103

Author(s):

Tejal Desai ◽

◽

Tristan Richardson ◽

Keyword(s):

Quality Of Life ◽

Abdominal Pain ◽

Life Expectancy ◽

Adrenal Insufficiency ◽

Unusual Case ◽

Primary Adrenal Insufficiency ◽

Prompt Treatment ◽

Bilateral Destruction ◽

Important Disease

Primary Adrenal Insufficiency is due to bilateral destruction of the adrenal cortex and has a prevalence of approximately 40-60 per million adults. 1 The commonest cause is autoimmune. 1 Prompt treatment not only restores quality of life but also a normal life expectancy. 2 Here we present an unusual case of primary adrenal insufficiency, which illustrates how such an important disease often provides a diagnostic conundrum.

Download Full-text

Eating Behaviors and Quality of Life in Preadolescents at Risk for Obesity With and Without Abdominal Pain

Journal of Pediatric Gastroenterology and Nutrition ◽

10.1097/mpg.0000000000000585 ◽

2015 ◽

Vol 60 (2) ◽

pp. 217-223 ◽

Cited By ~ 4

Author(s):

Michael D. Crowell ◽

Tasha B. Murphy ◽

Rona L. Levy ◽

Shelby L. Langer ◽

Alicia Kunin-Batson ◽

...

Keyword(s):

Quality Of Life ◽

At Risk ◽

Abdominal Pain ◽

Eating Behaviors

Download Full-text

Subjective judgements of quality of life: a comparison study between people with intellectual disability and those without disability

Journal of Intellectual Disability Research ◽

10.1046/j.1365-2788.2002.00343.x ◽

2002 ◽

Vol 46 (2) ◽

pp. 95-107 ◽

Cited By ~ 35

Author(s):

E. Hensel ◽

J. Rose ◽

B. Stenfert Kroese ◽

J. Banks-Smith

Keyword(s):

Quality Of Life ◽

Intellectual Disability ◽

Comparison Study

Download Full-text

Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program “odyssey”

Terapevticheskii arkhiv ◽

10.26442/terarkh201890840-47 ◽

2018 ◽

Vol 90 (8) ◽

pp. 40-47 ◽

Cited By ~ 1

Author(s):

I V Maev ◽

Yu A Kucheravy ◽

V V Tsukanov ◽

E Yu Eremnia ◽

D N Andreev ◽

...

Keyword(s):

Quality Of Life ◽

Abdominal Pain ◽

Surgical Treatment ◽

Rating Scale ◽

Clinical Symptoms ◽

Gastrointestinal Symptoms ◽

Marked Change ◽

Numeric Rating Scale ◽

Observational Assessment

Aim: to assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment. Materials and methods. 218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other post-cholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. Results and discussion. All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course (“prolonged population”). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, speficially related to the quality of life subscore ‘symptoms’. Conclusion. The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy.

Download Full-text